Endo Health downgraded to Neutral from Overweight at Piper Jaffray

theflyonthewall.com

Piper Jaffray downgraded Endo Health citing risk to the company's 2013 outlook and uncertainty on Opana ER. The firm lowered its price target for shares to $28 from $37.

Rates

View Comments (0)